Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-11-28
2006-11-28
McKane, Joseph K. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S236800, C514S256000, C514S342000, C544S134000, C544S335000, C546S271100
Reexamination Certificate
active
07141596
ABSTRACT:
The present invention provides compounds that can modulate the activity of a target protein, such as a phosphatase, that selectively binds phosphorylated peptides or proteins. The present compounds can be useful in treating diseases or disorders, including, for example, diabetes and obesity, that are connected directly or indirectly to the activity of the target protein.
REFERENCES:
patent: 4428956 (1984-01-01), Cragoe, Jr. et al.
patent: 5276049 (1994-01-01), Himmelsbach et al.
patent: 5478942 (1995-12-01), Himmelsbach et al.
patent: 5650424 (1997-07-01), Himmelsbach et al.
patent: 5789374 (1998-08-01), Sprecker et al.
patent: 5798374 (1998-08-01), Tang et al.
patent: 5852192 (1998-12-01), Himmelsbach et al.
patent: 6001867 (1999-12-01), Wrobel et al.
patent: 6057316 (2000-05-01), Wrobel et al.
patent: 6110963 (2000-08-01), Malamas
patent: 6166069 (2000-12-01), Malamas et al.
patent: 6310081 (2001-10-01), Malamas et al.
patent: 6479493 (2002-11-01), Whitehead et al.
patent: 2002/0086853 (2002-07-01), Cherney et al.
patent: 2003/0060419 (2003-03-01), Hu et al.
patent: 2004/0167188 (2004-08-01), Xin et al.
patent: WO 97/40017 (1997-10-01), None
patent: WO 98/27065 (1998-06-01), None
patent: WO 98/27092 (1998-06-01), None
patent: WO 98/53814 (1998-12-01), None
patent: WO 98/56376 (1998-12-01), None
patent: WO 99/11606 (1999-03-01), None
patent: WO 99/58514 (1999-11-01), None
patent: WO 99/58518 (1999-11-01), None
patent: WO 99/58519 (1999-11-01), None
patent: WO 99/58521 (1999-11-01), None
patent: WO 99/58522 (1999-11-01), None
patent: WO 99/61410 (1999-12-01), None
patent: WO 00/17211 (2000-03-01), None
patent: WO 00/53583 (2000-09-01), None
patent: WO 00/69899 (2000-11-01), None
patent: WO 01/16097 (2001-03-01), None
patent: WO 01/16122 (2001-03-01), None
patent: WO 01/16123 (2001-03-01), None
patent: WO 01/17516 (2001-03-01), None
patent: WO 01/19830 (2001-03-01), None
patent: WO 01/19831 (2001-03-01), None
patent: WO 01/46203 (2001-06-01), None
patent: WO 01/46204 (2001-06-01), None
patent: WO 01/46205 (2001-06-01), None
patent: WO 01/46206 (2001-06-01), None
patent: WO 01/70753 (2001-09-01), None
patent: WO 01/70754 (2001-09-01), None
patent: WO 02/04412 (2002-01-01), None
patent: WO 02/11722 (2002-02-01), None
patent: WO 02/012359 (2002-02-01), None
patent: WO 02/18321 (2002-03-01), None
patent: WO 02/18323 (2002-03-01), None
patent: WO 02/18363 (2002-03-01), None
patent: WO 02/26707 (2002-04-01), None
patent: WO 02/26743 (2002-04-01), None
patent: WO 02/28846 (2002-04-01), None
patent: WO 03/32916 (2003-04-01), None
patent: WO 03/033496 (2003-04-01), None
patent: WO 03/037328 (2003-05-01), None
patent: WO 03/82841 (2003-10-01), None
patent: WO 03/092679 (2003-11-01), None
patent: WO 04/041799 (2004-05-01), None
patent: WO 04/050646 (2004-06-01), None
patent: WO 04/062664 (2004-07-01), None
patent: WO 04/106305 (2004-12-01), None
Unterhalt et al., “Investigations of the cross reactivity of isothiazol-3(2 H)-one 1,1-dioxides,” Pharmazie, vol. 52, Iss. 11, pp. 764-766 (1998).
Arbuzov et al., “Reaction of azomethines with acylisocyanates in the presence of sulfur dioxide,”Izvestiya Akademii Nauk SSSR, Seriya Khimicheskaya(1980) 5:1164. (Abstract only).
Arbuzov et al., “Synthesis of substituted 4-oxo-1,2,3,5-oxathiadiazine 2-oxides,”Izvestiya Akademii Nauk SSSR, Seriya Khimicheskaya(1975) 6:1438. (Abstract only).
Beebe et al., “Substrate recognition through a PDZ domain in tail-specific protease,”Biochemistry(2000) 39:3149-3155.
Breslav et al., “Dithioketal formation during synthesis of Bpa containing peptides,”Tetrahedron Letters(1997) 38:2219.
Bright et al., “Competitive particle concentration fluorescene immunoassays for measuring anti-diabetic drug levels in mouse plasma,”J. of Immunological Methods(1997) 207:23.
Chou et al., “The syntheses of triazole, sulfur-containing diazole and N-phenylthiatriazole biphenyltetrazoles as potential angiotensin II receptor antagonists,”J. of the Chinese Chemical Society(1996) 43:83-93.
Davlatyan et al., “Reaction of thionylanilines with cyanohydrins and a-aminoisobutyronitrile,”Armyanskii Khimicheskii Zhurnal(1976) 29:764. (Abstract only).
Durcy et al., “Synthesis of 1,2,5-thiadiazolidin-3-one, 1,1-dioxide derivatives and evaluation of their affinity for MHC class-II proteins,”Helvetica Chemica Acta(1999) 82:2432.
Gao et al., “Macrocyclization in the design of a conformationally contrained Grb2 SH2 domain inhibitors,”Bioorganic&Medicinal Chemistry Letters(2001) 11:1889-1892.
Liu et al., “Small peptides containing phosphotyrosine and adjacent αMe-phosphotyrosine or its mimetics as highly potent inhibitors of Grb2 SH2,”J. Med. Chem.(1999) 42:3737-3741.
Schoepfer et al. “Convergent synthesis of potent peptide inhibitors of the Grb-2-SH2 domain by palladium catalyzed coupling of a terminal alkyne,”Bioorganic&Medicinal Chemistry Letters(2001) 11:1201-1203.
Bower Michael J.
Combs Andrew P.
Crawley Matthew L.
Pruitt James R.
Sparks Richard B.
Freistein Andrew B.
Incyte Corporation
McKane Joseph K.
LandOfFree
Inhibitors of proteins that bind phosphorylated molecules does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of proteins that bind phosphorylated molecules, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of proteins that bind phosphorylated molecules will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3665452